Every 8-K that NeuroOne Medical Technologies Corporation (NMTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NMTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMTC filings page.
NeuroOne Medical Technologies Corporation (NMTC) expects preliminary, unaudited fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, up 38.4% year over year from approximately $2.7 million. For fiscal 2026, it expects product revenue of approximately $10.5 million, up 15.6% year over year and at the top of its previously announced $9.2 million to $10.5 million guidance range. The estimates are subject to year-end accounting and audit procedures.
NeuroOne received a $4.5 million product purchase order in September 2026. Approximately $1.0 million had shipped by September 30; shipments of the remaining $3.6 million are expected to begin during fiscal first quarter 2027 and extend into second quarter 2027, subject to manufacturing and delivery schedules. Open purchase orders for shipments through fiscal first quarter 2027 totaled $5.4 million as of September 30, 2026. Complete fourth-quarter and full-year results are expected in December 2026.
NeuroOne Medical Technologies Corporation (NMTC) reported successful completion of three large-animal procedures using its next-generation StereoCED™ platform for targeted brain drug delivery and electrophysiological monitoring. In two procedures, the company’s electrodes both delivered a study agent and recorded intracranial activity from the same targeted brain regions, which NeuroOne believes is a first in convection-enhanced delivery.
The procedures were conducted at the University of Minnesota as part of a preclinical epilepsy research program and were designed to establish technical feasibility and validate the robotic-assisted surgical and drug delivery workflow. NeuroOne states that development of StereoCED™ devices for animal use finished ahead of schedule, enabling earlier-than-anticipated sales, and expects to recognize related StereoCED™ revenue from this research program in fiscal Q4 2026. Development of devices for human investigational use is reported to be on track, with release planned by the end of fiscal Q4 2026 and a planned launch of human investigational clinical studies later in the quarter.
NeuroOne Medical Technologies Corporation reported fiscal Q3 2026 results showing solid top-line growth but continued losses. Product revenue rose 16% year-over-year to $2.0 million, driven mainly by higher sales of OneRF products. Product gross profit increased 29% to $1.2 million, with product gross margin expanding to a record 59.9% versus 53.9% a year earlier.
New product orders of $2.7 million during the quarter exceeded shipments of $2.0 million, increasing backlog to $1.7 million, and total product orders for fiscal 2026 reached $11.2 million. However, total operating expenses grew to $3.6 million from $2.8 million, leading to a net loss of $2.0 million compared with a $1.5 million loss in the prior-year quarter.
As of June 30, 2026, cash and cash equivalents were $2.0 million, down from $6.6 million as of September 30, 2025, and working capital was $3.7 million versus $7.9 million. The company raised $0.4 million in Q3 and $8.4 million cumulatively through its at-the-market offering program, and later added $1.0 million more. NeuroOne reported no debt and highlighted ISO 13485 certification and planned international expansion and new therapy launches, including the StereoCED drug delivery system for research and investigational clinical studies by fiscal year-end.
NeuroOne Medical Technologies Corporation is updating its at-the-market stock offering, filing a Prospectus Supplement for the offer and sale of up to $13.4 million of common shares through JonesTrading under its existing Capital on Demand Sales Agreement.
The shares will be issued under an effective registration statement, with sales made only by means of the updated prospectus. Honigman LLP provided a legal opinion on the validity of the shares, which is included as an exhibit to this report.
NeuroOne Medical Technologies announced that investors should no longer rely on its interim financial statements for the quarter ended March 31, 2026 because of revenue-recognition errors tied to modified customer purchase orders. The company will amend and restate its Form 10-Q and related disclosures.
The errors caused revenue and accounts receivable to be overstated by an estimated $529,000, gross profit to be overstated by about $296,000, and operating and net loss to be understated by about $296,000. Total assets were overstated by $296,000 and inventory understated by $233,000. The company attributes the issue in part to inadequately designed and implemented internal controls, but states that no intentional misconduct by management or employees was involved.
In the accompanying press release, NeuroOne notes the error reflects a one-time revenue overstatement of approximately $0.5 million against initially reported quarterly revenue of $2.4 million, with no impact on prior periods or cash as of March 31, 2026. The company says ongoing business activities are not affected and reaffirms product revenue guidance of at least $10.5 million for fiscal 2026.
NeuroOne Medical Technologies reported fiscal second quarter 2026 results for the period ended March 31, 2026. Product revenue reached $2.4 million, up 72% from $1.4 million a year earlier, driven by higher sales of OneRF products, and first-half product revenue grew to $5.3 million from $4.7 million.
Product gross margin in the quarter was 53.8%, with product gross profit of $1.3 million. The company recorded a quarterly net loss of $2.1 million, or $0.25 per basic and diluted share, compared with a $2.3 million net loss in the prior-year quarter.
As of March 31, 2026, NeuroOne held $2.8 million in cash and cash equivalents and $2.4 million in accounts receivable, with working capital of $5.7 million and no debt outstanding. Management highlighted 16 completed OneRF Trigeminal Neuralgia cases with all patients reportedly pain free and ongoing development across brain ablation, drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
NeuroOne Medical Technologies Corporation reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company previously received a deficiency letter on May 6, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days.
On April 30, 2026, Nasdaq notified NeuroOne that the closing bid price of its common stock had been at least $1.00 per share for 10 consecutive business days. As a result, Nasdaq considers the company back in compliance with Nasdaq Listing Rule 5550(a)(2), and the bid price matter is closed.
NeuroOne Medical Technologies announced a planned chief financial officer transition. Ronald McClurg intends to retire as CFO effective June 30, 2026, and will remain with the company as a Senior Advisor until December 31, 2026 to support an orderly handover.
Chief Operating Officer Christopher Volker will become CFO on July 1, 2026. The company highlights his prior senior roles at Abbott, Cardiovascular Systems and St. Jude Medical, as well as investment banking experience in healthcare and technology.
Volker’s base salary will increase to $350,000 with other key employment terms unchanged. NeuroOne and McClurg entered into a Transition and Release Agreement under which he continues current salary and benefits through his Retirement Date in exchange for a general release of claims and customary restrictive covenants.
NeuroOne Medical Technologies Corporation is enacting a 1-for-6 reverse stock split of its common stock. Every 6 existing shares will be reclassified into 1 new share, with no change to the total number of authorized shares or the $0.001 par value.
The split becomes effective at 5:00 p.m. Eastern Time on April 15, 2026, and NeuroOne’s stock will begin trading on a split-adjusted basis on April 16, 2026 under the symbol NMTC. Fractional share positions will not be issued; instead, affected stockholders will receive a cash payment equal to the market value of the fractional share. Equity incentive plan awards, options and warrants will be proportionally adjusted, and the company notes the reverse split may help it regain compliance with Nasdaq’s minimum bid price requirement.
NeuroOne Medical Technologies Corporation held its annual stockholder meeting and approved several key proposals, including a potential reverse stock split and changes to its equity incentive plan. Stockholders authorized the Board to implement a reverse stock split in a range from 1-for-2 to 1-for-15 of the outstanding common stock.
Two Class III directors, Jeffrey Mathiesen and Edward Andrle, were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, and approved an amendment to the 2025 Equity Incentive Plan. A total of 30,272,834 shares, representing approximately 59.72% of shares outstanding as of the record date, were present in person or by proxy.
NeuroOne Medical Technologies Corporation set April 3, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location, and voting items in a future proxy statement.
Because this date is more than 30 days later than the prior year’s meeting anniversary, stockholder proposals seeking inclusion in the 2026 proxy materials under Rule 14a-8 must be received at the company’s principal executive offices by March 4, 2026.
NeuroOne Medical Technologies Corporation reported fiscal first-quarter 2026 results and raised its outlook for the full year. For the quarter ended December 31, 2025, product revenue was $2.9 million, slightly below $3.3 million a year earlier due to a large initial stocking order in the prior-year period, but up 5.5% from $2.7 million in the previous quarter. Product gross profit was $1.6 million, or 54.2% of revenue.
The company reported a net loss of $1.4 million, or $0.03 per share, compared with net income of $1.8 million, or $0.06 per share, a year ago, when results included $3.0 million of one-time license revenue. As of December 31, 2025, NeuroOne held $3.6 million in cash and cash equivalents, $6.8 million of working capital, and no debt, and believes it is funded through fiscal 2026. Management now expects fiscal 2026 product revenue of at least $10.5 million, at least 17% higher than fiscal 2025.
NeuroOne Medical Technologies Corporation filed a current report stating that on December 17, 2025 it issued a press release announcing its financial results for the fiscal quarter and year ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and, along with Item 2.02, is treated as furnished rather than filed under the Exchange Act, which affects how it is incorporated into other Securities Act and Exchange Act filings. The company’s common stock trades on the Nasdaq Stock Market under the symbol NMTC.
NeuroOne Medical Technologies (NMTC) received a Nasdaq extension to regain compliance with the Nasdaq Capital Market’s Minimum Bid Price Requirement of $1.00 per share. Nasdaq granted a 180-day extension through May 4, 2026.
The extension has no immediate effect on the company’s listing; NMTC’s common stock remains fully listed on the Nasdaq Capital Market. The company previously had until November 3, 2025 to cure the deficiency and has not yet regained compliance.
NeuroOne plans to continue monitoring the closing bid price and to seek compliance within the extension period. If compliance is not regained by the new deadline, Nasdaq may notify the company that its common stock is subject to delisting, and the company would have the right to appeal to a Nasdaq Hearing Panel.
NeuroOne Medical Technologies Corporation reported an annual total product revenue of approximately $9.1M and held approximately $6.6M in cash and cash equivalents as of September 30, 2025. These figures were disclosed in a press release furnished on October 6, 2025 and signed by CEO David Rosa. The filing is an 8-K reporting the material event and includes an interactive data file.
NeuroOne Medical Technologies Corporation reported that on August 18, 2025 it received U.S. Food and Drug Administration 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System. This clearance allows the company to market the device for procedures that create radiofrequency lesions to treat pain, and for lesioning nerve tissue in functional neurosurgical procedures. The authorization gives NeuroOne regulatory approval to commercialize this system in the United States for these specific neurosurgical applications.
NeuroOne Medical Technologies Corporation filed an update about its existing at-the-market stock sales program. On August 15, 2025, the company filed a new Prospectus Supplement covering the potential offer and sale of up to $6.75 million of common shares through JonesTrading Institutional Services LLC as sales agent under a previously signed Capital on Demand Sales Agreement.
The shares will be issued under an effective registration statement, and any sales will be made only by means of the updated Prospectus. Honigman LLP provided a legal opinion on the validity of the shares, which is included as an exhibit to this report.
NeuroOne Medical Technologies Corporation filed a Form 8-K reporting a material event by submitting a Press Release dated August 14, 2025. The filing identifies the company’s common stock ticker as NMTC on The Nasdaq Stock Market and lists an exhibit reference Exhibit 99.1 for the press release and a cover page interactive data file. The document is signed by David Rosa, Chief Executive Officer. The filing text provided here is brief and does not include the press release content, financial results, or details about the reported material event.